Compared to monotherapy, combination therapy resulted in a greater reduction in glycated haemoglobin (HbA1c), body weight, fasting plasma glucose (FPG), 2 h postprandial glucose (2 h PG), systolic blood pressure (SBP), body mass index (BMI) and low-density lipoprotein cholesterol (LDL-C)
Insulin-like Growth Factor-1 Long Arginine 3, or IGF-1 LR3, is a modified, long-acting analogue of endogenous IGF-1
Novo Nordisk maintains first-to-market advantage with semaglutide across diabetes (Ozempic), obesity (Wegovy), and oral (Rybelsus) formulations, with the oral version launching in January 2026 following December 2025 FDA approval [3]
Targeting GPX2 to disrupt lipid homeostasis and enhance cisplatin sensitivity in diffuse gastric cancer
Subsequent work revealed that GSH contributed to gliotoxin sensitivity, since diamide, a GSH scavenger, was less toxic to A